Scott Biller
Biller currently serves as a strategic advisor to Agios Pharmaceuticals, after nearly a decade as the company’s chief scientific officer. During his tenure as CSO, he advanced seven molecules into the clinic, leading to two marketed therapies and multiple late-stage candidates. Previously, he was VP and head of global discovery chemistry at the Novartis Institutes for BioMedical Research and as VP, pharmaceutical candidate optimization at the Bristol Myers Squibb Pharmaceutical Research Institute.
- October 2021
Added to: ROME Therapeutics - Cambridge, MA
ROME Therapeutics is a biotechnology company that is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome - vast stretches of uncharted genetic material that have long been dismissed as "junk DNA."